Annual report
4548.TEDINET S100R98T
Period2022-04-01 → 2023-03-31
Filed2023-06-29
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥34.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥27.7bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥29.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥27.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.1bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥4.5bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥5.4bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.0bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥4.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.9bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥5.4bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥10.8bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.2bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.2bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥3.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥75.6bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥75.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥69.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥68.7bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥80.2bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥8.4bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥8.9bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥67.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥66.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥63.6bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥59.8bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥73.0bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥23.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥21.5bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥25.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥23.4bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.0bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥7.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥8.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.7bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.1bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥3.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥870m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥1.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥623m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.5bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥3.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.8bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥40.49 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.32 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.54 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-192.15 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥39.76 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥1,232.41 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,179.46 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,127.14 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,059.4 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,294.88 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 88.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.0% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.0% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 3.3% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.7% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.9% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | -16.3% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 976 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 937 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 913 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 868 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 744 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥22.1bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥25.2bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥21.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥23.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥22.3bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥0 | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥2.3bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥3.7bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.2bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥3.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥1.8bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥2.5bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥3.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥11.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.4bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥63.1bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥64.6bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥62.4bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥62.7bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥75.2bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥6.4bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥6.6bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥56.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥58.0bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥57.8bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥55.0bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥68.6bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥18.1bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥17.2bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥32.55 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.34 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.86 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-201.73 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.57 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥26 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥26 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,039.07 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,031.37 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,024.93 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥975.56 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,216.16 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 89.9% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.8% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.2% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.1% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.3% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -18.4% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 56,814,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 56,814,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 540 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 531 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 523 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 519 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 514 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| LALreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥634m |
| LALreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥300m |
| LALreportable segment | employees | at 2023-03-31 | 303 pure |
| LALreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥10.7bn |
| LALreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥10.7bn |
| LALreportable segment | segment assets | at 2023-03-31 | ¥13.2bn |
| LALreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.3bn |
| Pharmaceuticalreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| Pharmaceuticalreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥851m |
| Pharmaceuticalreportable segment | employees | at 2023-03-31 | 563 pure |
| Pharmaceuticalreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥22.7bn |
| Pharmaceuticalreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥22.7bn |
| Pharmaceuticalreportable segment | segment assets | at 2023-03-31 | ¥62.4bn |
| Pharmaceuticalreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥143m |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥1.2bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥33.5bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥33.5bn |
| —segment total | segment assets | at 2023-03-31 | ¥75.6bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥2.1bn |
| LALreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥732m |
| LALreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥218m |
| LALreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥9.2bn |
| LALreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥9.2bn |
| LALreportable segment | segment assets | at 2022-03-31 | ¥10.8bn |
| LALreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.3bn |
| Pharmaceuticalreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥1.5bn |
| Pharmaceuticalreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥652m |
| Pharmaceuticalreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥25.7bn |
| Pharmaceuticalreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥25.7bn |
| Pharmaceuticalreportable segment | segment assets | at 2022-03-31 | ¥64.5bn |
| Pharmaceuticalreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥2.2bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥870m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥34.9bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥34.9bn |
| —segment total | segment assets | at 2022-03-31 | ¥75.2bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥4.5bn |
| LALreportable segment | employees | at 2023-03-31 | 12 pure |
| Pharmaceuticalreportable segment | employees | at 2023-03-31 | 418 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,588
| Item | Context | Value | Unit |
|---|---|---|---|
| Other net inv cf | CurrentYearDuration | -36000000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | 870000000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | 3365000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YearDuration | -87000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYearDuration | － | JPY |
| Purchase of treasury stock fin cf | Prior1YearDuration | -221000000 | JPY |
| Purchase of treasury stock fin cf | CurrentYearDuration | -1500000000 | JPY |
| Cash dividends paid fin cf | Prior1YearDuration | -1633000000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -1560000000 | JPY |
| Repayments of lease obligations fin cf | Prior1YearDuration | -40000000 | JPY |
| Repayments of lease obligations fin cf | CurrentYearDuration | -43000000 | JPY |
| Repayments of sales and instalment back transactions fin cf | Prior1YearDuration | -167000000 | JPY |
| Repayments of sales and instalment back transactions fin cf | CurrentYearDuration | -140000000 | JPY |
| Other net fin cf | Prior1YearDuration | -0 | JPY |
| Other net fin cf | CurrentYearDuration | -0 | JPY |
| Net cash provided by used in financing activities | Prior1YearDuration | -2151000000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | -3244000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YearDuration | 689000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | 735000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YearDuration | 7599000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 2430000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 15767000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 23367000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 23367000000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 25798000000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 5 | |
| Contract liabilities | Prior1YearInstant | 569000000 | JPY |
| Contract liabilities | CurrentYearInstant | 568000000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 9005000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 7951000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00970-000PharmaceuticalReportableSegmentsMember | 25696000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E00970-000LALReportableSegmentsMember | 9155000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 34851000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 34851000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00970-000PharmaceuticalReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E00970-000LALReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00970-000PharmaceuticalReportableSegmentsMember | 25696000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E00970-000LALReportableSegmentsMember | 9155000000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 34851000000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YearDuration | 34851000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00970-000PharmaceuticalReportableSegmentsMember | 2213000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E00970-000LALReportableSegmentsMember | 2281000000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | 4495000000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YearDuration | 4495000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |